The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population

Author

  • Johanna I. Kiiski
  • Anna Tervasmäki
  • Liisa M Pelttari
  • Sofia Khan
  • Tuomo Mantere
  • Katri Pylkäs
  • Arto Mannermaa
  • Maria Tengström
  • Anders Kvist
  • Åke Borg
  • Veli-Matti Kosma
  • Anne Kallioniemi
  • Johanna Schleutker
  • Ralf Bützow
  • Carl Blomqvist
  • Kristiina Aittomäki
  • Robert Winqvist
  • Heli Nevanlinna

Summary, in English

Purpose: The FANCM c.5101C>T nonsense mutation was previously found to associate with breast cancer in the Finnish population, especially among triple-negative cases. Here, we studied the prevalence of three other FANCM variants: c.5791C>T, which has been reported to predispose to familial breast cancer, and the c.4025_4026delCT and c.5293dupA variants recently identified in Finnish cancer patients. Methods: We genotyped the FANCM c.5791C>T mutation in 4806 invasive breast cancer patients, including BRCA1/2 mutation negative familial cases and unselected cases, and in 2734 healthy population controls from four different geographical areas of Finland. The association of the mutation with breast cancer risk among patient subgroups was statistically evaluated. We further analyzed the combined risk associated with c.5101C>T and c.5791C>T mutations. We also genotyped 526 unselected ovarian cancer patients for the c.5791C>T mutation and 862 familial breast cancer patients for the c.4025_4026delCT and c.5293dupA variants. Results: The frequency of the FANCM c.5791C>T mutation was higher among breast cancer cases than in controls (OR 1.94, 95% CI 0.87–4.32, P = 0.11), with a statistically significant association with triple-negative breast cancer (OR 5.14, 95% CI 1.65–16.0, P = 0.005). The combined analysis for c.5101C>T and c.5791C>T carriers confirmed a strong association with breast cancer (OR 1.86, 95% CI 1.32–2.49, P = 0.0002), especially among the triple-negative patients (OR 3.08, 95% CI 1.77–5.35, P = 0.00007). For the other variants, only one additional c.4025_4026delCT carrier and no c.5293dupA carriers were observed. Conclusions: These results support the role of FANCM as a breast cancer susceptibility gene, particularly for triple-negative breast cancer.

Department/s

  • Breastcancer-genetics
  • Familial Breast Cancer
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2017-07-12

Language

English

Pages

217-226

Publication/Series

Breast Cancer Research and Treatment

Volume

166

Issue

1

Document type

Journal article

Publisher

Springer

Topic

  • Cancer and Oncology

Keywords

  • Breast cancer
  • DNA repair
  • Familial breast cancer
  • FANCM
  • Triple-negative breast cancer

Status

Published

Research group

  • Familial Breast Cancer

ISBN/ISSN/Other

  • ISSN: 0167-6806